Literature DB >> 27778257

Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience.

Jordan M Cloyd1, Matthew H G Katz1, Laura Prakash1, Gauri R Varadhachary2, Robert A Wolff2, Rachna T Shroff2, Milind Javle2, David Fogelman2, Michael Overman2, Christopher H Crane3, Eugene J Koay3, Prajnan Das3, Sunil Krishnan3, Bruce D Minsky3, Jeffrey H Lee4, Manoop S Bhutani4, Brian Weston4, William Ross4, Priya Bhosale5, Eric P Tamm5, Huamin Wang6, Anirban Maitra6, Michael P Kim1, Thomas A Aloia1, Jean-Nicholas Vauthey1, Jason B Fleming1, James L Abbruzzese7, Peter W T Pisters8, Douglas B Evans9, Jeffrey E Lee10.   

Abstract

BACKGROUND: The purpose of this study was to evaluate a single-institution experience with delivery of preoperative therapy to patients with pancreatic ductal adenocarcinoma (PDAC) prior to pancreatoduodenectomy (PD).
METHODS: Consecutive patients (622) with PDAC who underwent PD following chemotherapy and/or chemoradiation between 1990 and 2014 were retrospectively reviewed. Preoperative treatment regimens, clinicopathologic characteristics, operative details, and long-term outcomes in four successive time periods (1990-1999, 2000-2004, 2005-2009, 2010-2014) were evaluated and compared.
RESULTS: The average number of patients per year who underwent PD following preoperative therapy as well as the proportion of operations performed for borderline resectable and locally advanced (BR/LA) tumors increased over time. The use of induction systemic chemotherapy, as well as postoperative adjuvant chemotherapy, also increased over time. Throughout the study period, the mean EBL decreased while R0 margin rates and vascular resection rates increased overall. Despite the increase in BR/LA resections, locoregional recurrence (LR) rates remained similar over time, and overall survival (OS) improved significantly (median 24.1, 28.1, 37.3, 43.4 months, respectively, p < 0.0001).
CONCLUSIONS: Despite increases in case complexity, relatively low rates of LR have been maintained while significant improvements in OS have been observed. Further improvements in patient outcomes will likely require disruptive advances in systemic therapy.

Entities:  

Keywords:  Neoadjuvant therapy; Pancreatectomy; Pancreatic ductal adenocarcinoma; Pancreatoduodenectomy

Mesh:

Year:  2016        PMID: 27778257     DOI: 10.1007/s11605-016-3265-1

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  63 in total

1.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.

Authors:  Jordan M Winter; John L Cameron; Kurtis A Campbell; Meghan A Arnold; David C Chang; Joann Coleman; Mary B Hodgin; Patricia K Sauter; Ralph H Hruban; Taylor S Riall; Richard D Schulick; Michael A Choti; Keith D Lillemoe; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

2.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

3.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

4.  Non-metastatic Pancreatic Cancer: Resectable, Borderline Resectable, and Locally Advanced-Definitions of Increasing Importance for the Optimal Delivery of Multimodality Therapy.

Authors:  Douglas B Evans; Ben George; Susan Tsai
Journal:  Ann Surg Oncol       Date:  2015-06-30       Impact factor: 5.344

5.  Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas.

Authors:  K W Millikan; D J Deziel; J C Silverstein; T M Kanjo; J D Christein; A Doolas; R A Prinz
Journal:  Am Surg       Date:  1999-07       Impact factor: 0.688

6.  The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy.

Authors:  Christina L Roland; Matthew H G Katz; Ching-Wei D Tzeng; Heather Lin; Gauri R Varadhachary; Rachna Shroff; Milind Javle; David Fogelman; Robert A Wolff; Jean N Vauthey; Christopher H Crane; Jeffrey E Lee; Jason B Fleming
Journal:  Ann Surg Oncol       Date:  2015-09-08       Impact factor: 5.344

7.  Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability.

Authors:  Ronica H Nanda; Bassel El-Rayes; Shishir K Maithel; Jerome Landry
Journal:  J Surg Oncol       Date:  2015-06-12       Impact factor: 3.454

8.  Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.

Authors:  Cristina R Ferrone; Giovanni Marchegiani; Theodore S Hong; David P Ryan; Vikram Deshpande; Erin I McDonnell; Francesco Sabbatino; Daniela Dias Santos; Jill N Allen; Lawrence S Blaszkowsky; Jeffrey W Clark; Jason E Faris; Lipika Goyal; Eunice L Kwak; Janet E Murphy; David T Ting; Jennifer Y Wo; Andrew X Zhu; Andrew L Warshaw; Keith D Lillemoe; Carlos Fernández-del Castillo
Journal:  Ann Surg       Date:  2015-01       Impact factor: 12.969

9.  Pancreaticoduodenectomy with vascular resection: margin status and survival duration.

Authors:  Jennifer F Tseng; Chandrajit P Raut; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Eddie K Abdalla; Henry F Gomez; Charlotte C Sun; Christopher H Crane; Robert A Wolff; Douglas B Evans
Journal:  J Gastrointest Surg       Date:  2004-12       Impact factor: 3.452

10.  Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?

Authors:  Ioannis T Konstantinidis; Andrew L Warshaw; Jill N Allen; Lawrence S Blaszkowsky; Carlos Fernandez-Del Castillo; Vikram Deshpande; Theodore S Hong; Eunice L Kwak; Gregory Y Lauwers; David P Ryan; Jennifer A Wargo; Keith D Lillemoe; Cristina R Ferrone
Journal:  Ann Surg       Date:  2013-04       Impact factor: 12.969

View more
  35 in total

1.  Surgical, survival, and oncological outcomes after vascular resection in robotic and open pancreaticoduodenectomy.

Authors:  Bor-Uei Shyr; Shih-Chin Chen; Yi-Ming Shyr; Shin-E Wang
Journal:  Surg Endosc       Date:  2019-04-08       Impact factor: 4.584

2.  Long-term Quality of Life and Gastrointestinal Functional Outcomes After Pancreaticoduodenectomy.

Authors:  Casey J Allen; Danny Yakoub; Francisco Igor Macedo; Austin R Dosch; Jessica Brosch; Vikas Dudeja; Ronda Ayala; Nipun B Merchant
Journal:  Ann Surg       Date:  2018-10       Impact factor: 12.969

3.  Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy?

Authors:  Chad A Barnes; Ashley N Krepline; Mohammed Aldakkak; Callisia N Clarke; Kathleen K Christians; Abdul H Khan; Bryan C Hunt; Paul S Ritch; Ben George; William A Hall; Beth A Erickson; Douglas B Evans; Susan Tsai
Journal:  J Gastrointest Surg       Date:  2017-08-28       Impact factor: 3.452

4.  Surgery for pancreatic cancer: recent progress and future directions.

Authors:  Zachary J Brown; Jordan M Cloyd
Journal:  Hepatobiliary Surg Nutr       Date:  2021-06       Impact factor: 7.293

5.  ASO Author Reflections: It is Time to Prioritize Exercise in Pancreatic Cancer Survivorship.

Authors:  Nathan H Parker; Matthew H G Katz
Journal:  Ann Surg Oncol       Date:  2020-09-04       Impact factor: 5.344

6.  Factors Influencing Exercise Following Pancreatic Tumor Resection.

Authors:  Nathan H Parker; Karen Basen-Engquist; M Laura Rubin; Yisheng Li; Laura Prakash; An Ngo-Huang; Jessica Gorzelitz; Naruhiko Ikoma; Jeffrey E Lee; Matthew H G Katz
Journal:  Ann Surg Oncol       Date:  2020-09-04       Impact factor: 5.344

7.  Anthropometric Changes in Patients with Pancreatic Cancer Undergoing Preoperative Therapy and Pancreatoduodenectomy.

Authors:  Jordan M Cloyd; Graciela M Nogueras-González; Laura R Prakash; Maria Q B Petzel; Nathan H Parker; An T Ngo-Huang; David Fogelman; Jason W Denbo; Naveen Garg; Michael P Kim; Jeffrey E Lee; Ching-Wei D Tzeng; Jason B Fleming; Matthew H G Katz
Journal:  J Gastrointest Surg       Date:  2017-12-11       Impact factor: 3.452

8.  Patient experience and quality of life during neoadjuvant therapy for pancreatic cancer: a systematic review and study protocol.

Authors:  Jordan M Cloyd; Sarah Hyman; Tanya Huwig; Christina Monsour; Heena Santry; Celia Wills; Allan Tsung; John F P Bridges
Journal:  Support Care Cancer       Date:  2020-10-08       Impact factor: 3.603

9.  Preoperative Chemoradiation for Borderline Resectable Pancreatic Cancer: The New Standard?

Authors:  Matthew Hg Katz; Michael P Kim; Ching-Wei Tzeng; Jeffrey E Lee
Journal:  Ann Surg       Date:  2018-08       Impact factor: 12.969

Review 10.  Recent Advances in Pancreatic Cancer Surgery.

Authors:  Laura Maggino; Charles M Vollmer
Journal:  Curr Treat Options Gastroenterol       Date:  2017-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.